Keyphrases
Colorectal Cancer
100%
Metastasis
41%
Small Bowel Adenocarcinoma
40%
Phase II Study
35%
Mammalian Target of Rapamycin Signaling
34%
Mammalian Target of Rapamycin (mTOR)
33%
Confidence Interval
31%
Small Intestine
30%
Rapamycin
30%
Molecular Landscape
30%
AKT2
29%
Ampulla of Vater
29%
Gemcitabine
29%
Capecitabine
29%
AKT/mammalian Target of Rapamycin
29%
Pancreatic Ductal Adenocarcinoma
26%
Ampullary Adenocarcinoma
25%
MTOR Complex 2 (mTORC2)
23%
Tumorigenesis
22%
Phosphoinositide 3-kinase (PI3K)
22%
In Cancer
21%
Colorectal Cancer Metastases
20%
Metastatic Pancreatic Ductal Adenocarcinoma
20%
KRAS mutation
19%
Targeted Inhibition
18%
Single Center
18%
Metastatic Colorectal Cancer (mCRC)
17%
MTOR Inhibitor
17%
Attenuation
17%
Tumor Suppressor
17%
AKT Pathway
16%
PIK3CA
16%
Overexpression
16%
Carcinoid Tumor
16%
Expression Pattern
16%
Genetic Modification
16%
Therapeutic Strategies
16%
AKT1
16%
Epigenetic Modification
16%
Inhibits Proliferation
16%
Mammalian Target of Rapamycin Signaling Pathway
15%
Oxaliplatin
15%
First-line Systemic Therapy
14%
Immunological Response
14%
Panitumumab
14%
CXCR2
14%
4-1BB
14%
CXCR1
14%
Promoter Elements
14%
Neuromedin N
14%
Medicine and Dentistry
Colorectal Carcinoma
47%
Adenocarcinoma
43%
Pancreas Adenocarcinoma
40%
Mechanistic Target of Rapamycin
38%
Gemcitabine
29%
Ampulla of Vater
29%
Capecitabine
29%
Biliary Tract Cancer
29%
Cancer
23%
Neoplasm
21%
Overall Survival
20%
Immunotherapy
20%
Diseases
19%
Metastatic Carcinoma
19%
T Cell
18%
Cancer Therapy
17%
Systemic Therapy
17%
Carcinogenesis
16%
Rapamycin
16%
Oxaliplatin
16%
Mammalian Target of Rapamycin Inhibitor
16%
Phosphoinositide 3-Kinase
15%
Cell Signaling Pathway
15%
Receptor Expression
14%
Chemoradiotherapy
14%
Panitumumab
14%
DNA Repair
14%
Bevacizumab
14%
Pancreas Cancer
14%
Myeloid Cell
14%
Akt/mTOR Signaling
14%
Interleukin 8 Receptor, Beta
14%
Paclitaxel
14%
Growth Factor Receptor
14%
Metastatic Colorectal Cancer
14%
Carcinoembryonic Antigen
14%
Carcinoid
14%
Biliary Duct Cancer
14%
Drug Delivery System
14%
Mesenchymal-Epithelial Transition
14%
Gastrointestinal Cancer
14%
Immunity
14%
Radiation Therapy
14%
Prostate Cancer
14%
Fibroblast Growth Factor Receptor 2
14%
Immune Checkpoint Inhibitor
14%
Breast Cancer
14%
Hazard Ratio
12%
Surgery
10%
Protein Kinase B
9%
Biochemistry, Genetics and Molecular Biology
Mechanistic Target of Rapamycin
48%
Cancer Cell
48%
Protein Kinase B
36%
Colon
34%
Akt/mTOR Signaling
29%
KRAS
29%
Enzyme
26%
Genetics
24%
Epigenetics
21%
Wild Type
21%
Carcinogenesis
20%
T Cell
18%
Phosphoinositide 3-Kinase
17%
Overall Survival
14%
Tumor Progression
14%
Fatty Acid Synthase
14%
Mammalian Target of Rapamycin
14%
Tumor Suppressor Protein
14%
Reprogramming
14%
Pleckstrin Homology Domain
14%
Phosphoprotein Phosphatase
14%
Myeloid
14%
Leucine-Rich Repeat
14%
Catenin
14%
Immune Checkpoints
14%
Deubiquitination
14%
Akt Signaling
14%
DNA Repair
14%
Drug Targeting
14%
CD44
14%
LAG3
14%
Cytokine
14%
Mesenchymal-Epithelial Transition
14%
Neuromedin N
14%
Capecitabine
14%
Gemcitabine
14%
Poly ADP Ribose Polymerase
14%
Pribnow Box
14%
Neurotensin
14%
CHEK2
14%
Messenger RNA
13%
Lipogenesis
11%
Isoform
10%
mTOR Signaling
9%
Pi3K/Akt Signaling
9%
Programmed Cell Death
9%
Cell Proliferation
8%
Actin
7%
Chromatin Remodeling
7%
Phosphotransferase
7%
